tetano
Editor, Senior Moderator
Pediatr Infect Dis J. 2011 Dec 29. [Epub ahead of print]
Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1.
Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y, Loukas YL, Theodoridou M.
Source
1Department for Interventions in Health-Care Facilities, Hellenic Centre for Diseases Control and Prevention, Athens, Greece; 2Department of Pharmaceutical Technology, School of Pharmacy, University of Athens, Athens, Greece; 3Neonatal Unit of the University of Athens First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece; 4Laboratory of Biopharmaceutics Pharmacokinetics, School of Pharmacy, University of Athens, Athens, Greece; 5Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Athens, Greece; 6Laboratory of Prenatal and Neonatal Screening, Neoscreen Ltd., Athens, Greece, 7University of Athens First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece.
Abstract
Oseltamivir was administered at 1.0mg/kg b.i.d. to 13 neonates exposed to influenza H1N1. No influenza, neurologic or laboratory adverse effects occurred. The mean Cmax values for oseltamivir and oseltamivir carboxylate were found to be lower than those reported for children 1-5 years old, while Tmax values were similar to children 1-5 years old. Age and gender were found to significantly affect oseltamivir clearance.
PMID:
22209917
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22209917
Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1.
Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y, Loukas YL, Theodoridou M.
Source
1Department for Interventions in Health-Care Facilities, Hellenic Centre for Diseases Control and Prevention, Athens, Greece; 2Department of Pharmaceutical Technology, School of Pharmacy, University of Athens, Athens, Greece; 3Neonatal Unit of the University of Athens First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece; 4Laboratory of Biopharmaceutics Pharmacokinetics, School of Pharmacy, University of Athens, Athens, Greece; 5Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Athens, Greece; 6Laboratory of Prenatal and Neonatal Screening, Neoscreen Ltd., Athens, Greece, 7University of Athens First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece.
Abstract
Oseltamivir was administered at 1.0mg/kg b.i.d. to 13 neonates exposed to influenza H1N1. No influenza, neurologic or laboratory adverse effects occurred. The mean Cmax values for oseltamivir and oseltamivir carboxylate were found to be lower than those reported for children 1-5 years old, while Tmax values were similar to children 1-5 years old. Age and gender were found to significantly affect oseltamivir clearance.
PMID:
22209917
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22209917